P.E.A.k Activate 600 mg
Supports cellular homeostasis
- Scientifically shown to help reduce chronic pain and inflammation
- A naturally occurring long-chain fatty acid amide generally produced in response to various triggers including inflammation
- Studied for 80 years and by more than 300+ medical studies
$49.94 — or subscribe and save 20%
Palmitoylethanolamide (PEA) is a long-chain fatty acid naturally produced by the body but also found in foods such as egg yolk, soy, and sunflower oils. This molecule, researched for its unique and varied health benefits for eighty years, is now receiving attention because of its crucial role in the endocannabinoid system (ECS). The ECS is a lipid communication network with critical physiological functions. It is a signaling network that communicates with other systems throughout the body, helping to regulate them. PEA is an endocannabinoid produced locally by the cells, and it accumulates in tissues following an injury, physical stress, or pain.
By inhibiting the activation of mast cells that cause additional inflammation (such as the release of histamine), PEA acts as a potent anti-inflammatory agent. This unique molecule has other direct and indirect mechanisms of action; it even enhances the action of other endocannabinoids through its “entourage effect”. The PEA molecule has been clinically demonstrated to relieve pain in osteoarthritis of the knee as well as to reduce symptoms of low back pain. This mighty little molecule is well tolerated.
AOR is leading the way by transforming the impressive and evolving research on PEA’s positive effects within the human endocannabinoid system, bringing you a safe and therapeutic formulation to combat chronic pain and systemic inflammation. The PEA in AOR’s P.E.A.k Activate is produced in Italy and originally extracted from environmentally sustainable Malaysian palm oil that is purified and responsibly processed for optimal bioavailability.
Also available in a 400 mg capsule. To learn more visit https://aorpea.ca
Palmitoylethanolamide (PEA) is a plant-based bioactive functional lipid with pleiotropic effects. Studies show that PEA may be used as an anti-inflammatory to help relieve chronic pain.
AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.
Chew, dissolve or swallow one lozenge two times a day, with or without food; or as directed by a health care practitioner.
For use beyond 40 days, consult a healthcare practitioner. Consult a healthcare practitioner prior to use if you are pregnant or breastfeeding. Consult a health care practitioner if symptoms persist or worsen.
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
ǂ Genuine Italian Source
Non-medicinal ingredients: ascorbyl palmitate, isomalt, watermelon flavor, maltodextrin, modified food starch, xanthan gum, monk fruit extract, hydroxypropyl cellulose and microcrystalline cellulose.
PEA in Pain a Meta-analysis
This 2017 meta-analysis using randomized controlled trials, to determine the efficacy and safety of PEA for treating chronic pain. Ten studies were identified for review, eight of these studies were randomized controlled trials with 743 patients receiving PEA and 460 patients receiving inactive controls. Analysis of the results of these trials found that PEA supplementation led to significantly greater pain reduction compared to controls. The dosages of PEA ranged from 300 mg/day to 1200 mg/day with most showing optimal benefit at 600 mg/day or greater for supplementation from 10-180 days. Further, researchers found that PEA treatment groups had fewer dropouts due to adverse events as compared with placebo or no treatment groups. The few reported adverse events included GI upset, drowsiness, and heart palpitations.
Artukoglu BB, Beyer C, Zuloff-Shani A, Brener E, Bloch MH. Efficacy of Palmitoylethanolamide for Pain: A Meta-Analysis. Pain Physician. 2017;20(5):353-362. https://pubmed.ncbi.nlm.nih.gov/28727699/
PEA vs Celecoxib for Pelvic Pain
In a double-blind, randomized controlled with three treatment arms (PEA, placebo, or celecoxib) of 61 patients with chronic pelvic pain due to endometriosis who were a candidate for laparoscopic conservative surgery. Groups were given either: 800 mg daily of PEA (n=21) N-Palmitoylethanolamine–transpolydatin 400 mg + 40 mg twice a day for three months; or the placebo (n = 20) for three months; OR a single course of Celecoxib 200 mg twice a day for seven consecutive days (n = 20). Objective measurements of the severity of pelvic endometriosis (pelvic pain, dysmenorrhoea, and dyspareunia) along with a 10-point VAS questionnaire. Results showed a significantly reduced pain intensity in comparison to placebo at three months for the PEA and celecoxib groups. However, celecoxib (a nonsteroidal anti-inflammatory drug) and PEA did not differ significantly in terms of pain reduction.
Cobellis L, Castaldi MA, Giordano V, Trabucco E, De Franciscis P, Torella M, et al. Effectiveness of the association micronized N- Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study. Eur J Obstet Gynecol Reprod Biol 2011; 158: 82–6. https://pubmed.ncbi.nlm.nih.gov/21601979/
PEA in TMJ Pain
In a triple-blind RCT published in 2012, investigating the effectiveness of PEA vs ibuprofen in 24 patients with temporomandibular joint inflammatory pain for two weeks. The first treatment group receives PEA 300 mg in the morning and 600 mg in the evening for seven days and then 300 mg twice a day for seven more days. A second group receives 600 mg TID of ibuprofen daily for two weeks (n=12). Outcomes were based on the frequency and intensity of spontaneous pain measured by the visual analog scale- recorded by patients twice a day. PEA administration resulted in a larger reduction in pain intensity on day 14. With adverse effects only being reported in the ibuprofen group.
Marini I, Bartolucci ML, Bortolotti F, Gatto MR, Bonetti GA. Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. J Orofac Pain 2012; 26: 99–104. https://pubmed.ncbi.nlm.nih.gov/22558609/
Diabetic Peripheral Neuropathy and PEA Supplementation
Neuropathic pain due to conditions such as diabetes is a common serious complication of the disease. Patients who were suffering from painful diabetic neuropathies (n=30) were recruited for this 60-day open-label study. Pain severity was assessed using a number of assessment tools including Michigan Neuropathy Screening instrument; the intensity of symptoms by the Total Symptom Score; and the Neuropathic Pain Symptoms Inventory. Hematological and blood chemistry tests to evaluate metabolic control and safety. Micronized and ultra-micronized formulations of PEA (300mg/day) administered orally reduces pain scores in diabetic patients with peripheral neuropathy.
Schifilliti C, Cucinotta L, Fedele V, Ingegnosi C, Luca S, Leotta C. Micronized palmitoylethanolamide reduces the symptoms of neuropathic pain in diabetic patients. Pain Res Treat. 2014;2014:849623. https://pubmed.ncbi.nlm.nih.gov/24804094/
High Dose Management for Diabetic Neuropathies
This study published in 2014 assessed the impact of additional PEA supplementation in Pregabalin, Gabapentin, and/or Tramadol treatment-resistant individuals (n=30). Subjects recruited had diabetic or traumatic chronic neuropathic pain, not controlled by other oral conventional therapies suffering from chronic pain for at least 100 days at the time of recruitment. Using the Visual Analogue Scale (VAS) as a measure of pain subjects were provided with oral PEA 1200 mg/day in sachet formulation for the first 10 days and 1200 mg/day in tablet formulation between the 10th and 40th days. Researchers found that ultra-micronized PEA 1200 mg orally reduced the neuropathic pain symptom inventory scores of patients with diabetic or traumatic neuropathic pain.
Cocito D, Peci E, Ciaramitaro P, Merola A, Lopiano L. Short-term efficacy of ultramicronized palmitoylethanolamide in peripheral neuropathic pain. Pain Res Treat. 2014;2014:854560 https://pubmed.ncbi.nlm.nih.gov/24967102/
PEA in Neuropathic Pain Meta-analysis
A meta-analysis by Paladini et al. published in 2016 evaluated the safety and efficacy of micronized and ultra-micronized PEA confirmed that it produced analgesia in patients with chronic or neuropathic pain in a manner that was independent of age and gender. Twelve studies were included (three were double-blind trials, two were open-label trials vs standard therapies, and seven were open-label trials without comparators.) The authors concluded that PEA elicits a progressive reduction of pain intensity significantly higher than control- the magnitude of reduction is 1.04 points (vs 0.2 points in placebo) every two weeks (35% response variance.) Making it an effective option for neuropathic pain management.
Paladini A, Fusco M, Cenacchi T, Schievano C, Piroli A, Varrassi G. Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis. Pain Physician. 2016;19(2):11-24. https://pubmed.ncbi.nlm.nih.gov/26815246/
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis, and amyotrophic lateral sclerosis (ALS), are characterized by gradual, selective neuronal loss, leading to cognitive deficits, dementia, behavioural impairment, and motor abnormalities. In a clinical study by Palma et al. 64 patients were randomized to receive riluzole 50 mg (a drug used to treat amyotrophic lateral sclerosis [ALS]) plus micronized PEA 600 mg, or riluzole only. ALS patients treated with riluzole plus micronized PEA benefited from a reduction in worsening of respiratory function, and reduced rates of surgical procedures and reduced mortality, in comparison to patients who received riluzole only. This suggests that PEA may provide benefit by contributing to the slowing of disease progression of neurodegenerative disease.
Palma E, Reyes-Ruiz JM, Lopergolo D, Roseti C, Bertollini C, Ruffolo G, et al. Acetylcholine receptors from human muscle as pharmacological targets for ALS therapy. Proc Natl Acad Sci U S A. 2016;113(11):3060-5. https://www.pnas.org/content/113/11/3060
In a 2016 observational study of 250 stroke patients, Caltagirone et al. demonstrated that co-administration of ultra-micronized PEA and luteolin was associated with improved neurological status, spasticity, cognitive abilities, pain, and independence in daily living activities after 30 days of treatment.
Caltagirone C, Cisari C, Schievano C, Di Paola R, Cordaro M, Bruschetta G, et al. Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man. Transl Stroke Res. 2016;7(1):54-69 https://pubmed.ncbi.nlm.nih.gov/26706245/
In an observational database study of 2456 patients with atopic eczema, patients reported a significant reduction in eczema symptoms (pruritis, erythema, scaling and dryness) after 6 weeks, in addition to an improvement in sleep quality. Patients also reported reduced usage of topical corticosteroids during the study period.
Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Euro Acad Dermatol Venereol. 2008;22:73-82. https://pubmed.ncbi.nlm.nih.gov/18181976/